Caris Life Sciences CAI
NASDAQ CAI
$24.76 -0.56 (-2.19%)
As of: Sep 4, 2026 · 2:29 PM EDT

Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Income from Continuing Operations of 510000.0 for Q1 2026, up 99.5% year-over-year from 255635.47 in Q1 2025, and down 100.62% quarter-over-quarter from 81957000.0 in Q4 2025.

Analysis

Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026) Analysis & Trends

Caris Life Sciences' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 510000.0 for Q1 2026.

  • In Q1 2026, Income from Continuing Operations rose 99.5% year-over-year to 510000.0; the TTM figure through Mar 2026 stood at 33982000.0 (up 112.43% YoY), while the FY2025 annual figure was 68088000.0, up 75.85% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 510000.0, down from 81957000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 81957000.0 in Q4 2025, with the low at 102581000.0 in Q1 2025.
  • The 3-year median for Income from Continuing Operations is 51566500.0 (2024), against an average of 29932625.0.
  • Peak annual rise in Income from Continuing Operations reached 321.82% in 2025, while the deepest fall reached 8.47% in 2025.
  • Caris Life Sciences' Income from Continuing Operations stood at 36947000.0 in 2024, then surged by 321.82% to 81957000.0 in 2025, then plunged by 100.62% to 510000.0 in 2026.
  • Business Quant data shows CAI's Income from Continuing Operations at 510000.0 in Q1 2026, 81957000.0 in Q4 2025, and 24325000.0 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - -644.37 Mn
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - 81.49 Mn
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn -13.27 Mn
10 Caris Life Sciences 7.01 Bn 6.22 Bn 182.38 Mn -637,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -637,000.00
Mar 31, 2026 -510,000.00
Dec 31, 2025 81.96 Mn
Sep 30, 2025 24.33 Mn
Jun 30, 2025 -71.79 Mn
Mar 31, 2025 -102.58 Mn
Dec 31, 2024 -36.95 Mn
Sep 30, 2024 -67.73 Mn
Jun 30, 2024 -66.19 Mn